Arrhythmogenic cardiomyopathy

what blood can reveal?

Research output: Contribution to journalArticle

Abstract

Blood, serum and plasma represent accessible sources of data about physiological and pathologic status. In arrhythmogenic cardiomyopathy (ACM), circulating nucleated cells are routinely used for detection of germinal genetic mutations. In addition, different biomarkers have been proposed for diagnostic purposes and for monitoring disease progression, including inflammatory cytokines, markers of myocardial dysfunction and damage, and microRNAs. This review summarizes the current information that can be retrieved from the blood of ACM patients and considers the future prospects. Improvements in current knowledge of circulating factors may provide noninvasive means to simplify and improve the diagnosis, prognosis prediction, and management of ACM patients.

Original languageEnglish
JournalHeart Rhythm
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Cardiomyopathies
Information Storage and Retrieval
MicroRNAs
Disease Progression
Biomarkers
Cytokines
Mutation
Serum

Keywords

  • Arrhythmogenic right ventricular cardiomyopathy
  • Biomarkers
  • Blood
  • Genetics
  • Heart failure
  • Inflammation
  • microRNA
  • Plasma
  • Serum

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

@article{0fb0a14aa2fa4d3581bfbbf1b7736154,
title = "Arrhythmogenic cardiomyopathy: what blood can reveal?",
abstract = "Blood, serum and plasma represent accessible sources of data about physiological and pathologic status. In arrhythmogenic cardiomyopathy (ACM), circulating nucleated cells are routinely used for detection of germinal genetic mutations. In addition, different biomarkers have been proposed for diagnostic purposes and for monitoring disease progression, including inflammatory cytokines, markers of myocardial dysfunction and damage, and microRNAs. This review summarizes the current information that can be retrieved from the blood of ACM patients and considers the future prospects. Improvements in current knowledge of circulating factors may provide noninvasive means to simplify and improve the diagnosis, prognosis prediction, and management of ACM patients.",
keywords = "Arrhythmogenic right ventricular cardiomyopathy, Biomarkers, Blood, Genetics, Heart failure, Inflammation, microRNA, Plasma, Serum",
author = "Ilaria Stadiotti and Giulio Pompilio and Maione, {Angela Serena} and Pilato, {Chiara Assunta} and Yuri D'Alessandra and Elena Sommariva",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.hrthm.2018.09.023",
language = "English",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",

}

TY - JOUR

T1 - Arrhythmogenic cardiomyopathy

T2 - what blood can reveal?

AU - Stadiotti, Ilaria

AU - Pompilio, Giulio

AU - Maione, Angela Serena

AU - Pilato, Chiara Assunta

AU - D'Alessandra, Yuri

AU - Sommariva, Elena

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Blood, serum and plasma represent accessible sources of data about physiological and pathologic status. In arrhythmogenic cardiomyopathy (ACM), circulating nucleated cells are routinely used for detection of germinal genetic mutations. In addition, different biomarkers have been proposed for diagnostic purposes and for monitoring disease progression, including inflammatory cytokines, markers of myocardial dysfunction and damage, and microRNAs. This review summarizes the current information that can be retrieved from the blood of ACM patients and considers the future prospects. Improvements in current knowledge of circulating factors may provide noninvasive means to simplify and improve the diagnosis, prognosis prediction, and management of ACM patients.

AB - Blood, serum and plasma represent accessible sources of data about physiological and pathologic status. In arrhythmogenic cardiomyopathy (ACM), circulating nucleated cells are routinely used for detection of germinal genetic mutations. In addition, different biomarkers have been proposed for diagnostic purposes and for monitoring disease progression, including inflammatory cytokines, markers of myocardial dysfunction and damage, and microRNAs. This review summarizes the current information that can be retrieved from the blood of ACM patients and considers the future prospects. Improvements in current knowledge of circulating factors may provide noninvasive means to simplify and improve the diagnosis, prognosis prediction, and management of ACM patients.

KW - Arrhythmogenic right ventricular cardiomyopathy

KW - Biomarkers

KW - Blood

KW - Genetics

KW - Heart failure

KW - Inflammation

KW - microRNA

KW - Plasma

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=85057591965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057591965&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2018.09.023

DO - 10.1016/j.hrthm.2018.09.023

M3 - Article

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

ER -